All News

The results of a new study show that when coronavirus-infected diabetic mice were injected with an interferon beta, SETDB2 increased and helped decrease the inflammatory cytokines.

Six-point plan outlines strategies to increase national vaccination rates, keep schools open, increase testing and masking access, and to relieve health systems that are overrun with COVID-19 patients.

The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.

Calibrations for the European Randomized Study on Prostate Cancer and Prostate Cancer Prevention Trial predictors can forecast cases across different groups than originally targeted.

Because asparaginase is used exclusively in ALL, most adult oncologists do not administer it routinely.

Empagliflozin demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure, compared with placebo.

Investigators used a new animal model to determine how the stem-like T cell can survive and what it looks like over the course of several months of tumor growth.

Concepts could be used in payer-pharmacy value-based arrangements.

A new study explores why individuals who suffer most from the condition have the worse symptoms at night.

Racial or ethnic discrimination can appear in many ways, even as discrimination against someone based on their accent.

Prostate cancers grow slowly and rarely cause any health problems, so without regular screening, it is more difficult to identify any cancer in the prostate.

Vaccines help prevent pneumococcal disease, which is any type of illness caused by Streptococcus pneumoniae bacteria.

Pharmacists can be instrumental in reducing the main challenges in opioid use disorder—namely supply, demand, and harm.

The results of a new study show a new view of genetic regulation by uncovering how genes and disease are related.

Although the cardiovascular condition was thought to be benign, the disease could put pregnant women at greater risk for serious complications during childbirth.

Ado-trastuzumab (Kadcyla, Genentech) was approved by the FDA in 2019 for the adjuvant treatment of patients with human epidermal growth factor receptor 2-positive early breast cancer.

Study results show that blood and urine exams can potentially pinpoint and track bladder malignancies and nerve tumors.

Nearly 20% of patients with multiple myeloma have a form of the disease in which they make high quantities of a component of monoclonal proteins, which damages the kidneys.

The results of a new study show that exposure to the viruses produces a protective ‘universal coronavirus’ memory.

The investigators said that even patients with asthma showed no statistically significant deterioration in lung function, although there was a trend toward slightly lower measurements for the amount of air they could exhale forcibly in 1 second.

Bleeding in the upper GI tract is among the most common bleeding complications following acute myocardial infarction, causing considerable suffering and increasing the risk of death.

This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.

The results of a new study show that immunizations may help prevent malignancies in individuals aged 36 to 45 years.

Ulcerative colitis affects the innermost lining of your large intestine and rectum.

The results of a study show that with proper antibiotic treatments and therapy, clinical outcomes for those with community-acquired pneumonia do not differ.

Study results show that these personalized treatments adjust based on cerebral function through electric pulses.

Investigators find a precision medicine that can identify those with the rare disorder who may benefit from FDA-approved siltuximab.

From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.

In a study, 92.5% of patients treated with the 6-month regimen of Invega and 95% of patients treated with the 3-month regimen were relapse-free at 12 months.

Diabetic kidney disease develops in nearly 40% of patients with diabetes and serves as the leading cause of chronic kidney disease worldwide, according to the study.